Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination

Alexandra Tauzin, Mehdi Benlarbi, Halima Medjahed, Yves Grégoire, Josée Perreault, Gabrielle Gendron-Lepage, Laurie Gokool, Chantal Morisseau, Pascale Arlotto, Cécile Tremblay, Daniel E. Kaufmann, Valérie-Martel-Laferrière, Inès Levade, Marceline Côté, Gaston de Serres, Renée Bazin, Andrés Finzi
doi: https://doi.org/10.1101/2022.12.20.22283723

Abstract

The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many countries. Because of the many mutations present in its Spike glycoprotein, this variant is resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to improve immune responses against Omicron subvariants, bivalent mRNA vaccines have recently been approved in several countries. In this study, we measure the capacity of plasma from vaccinated individuals, before and after a fourth dose of mono-or bivalent mRNA vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before and after the fourth dose, we observe a significantly better recognition and neutralization of the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been recently infected recognize and neutralize better the BQ.1.1 Spike, independently of the mRNA vaccine used, than donors who have never been infected or have an older infection. Our study supports that hybrid immunity, generated by vaccination and a recent infection, induces higher humoral responses than vaccination alone, independently of the mRNA vaccine used.

Introduction

The Omicron BQ.1.1 variant is a sublineage of the BA.5 variant that spreads very rapidly and is now the major circulating lineage in several countries [1,2]. Recent studies have shown that original SARS-CoV-2 mRNA vaccines, based on the ancestral Wuhan strain Spike (S), lead to poor humoral responses against several Omicron subvariants, including the BQ.1.1 variant [3–5]. With the goal to improve immune responses against these subvariants, Moderna and Pfizer bivalent vaccines have recently been approved by health authorities in many countries [6–8]. These updated versions of the vaccines are composed of mRNA coding for the expression of both the ancestral and an Omicron subvariant S [9,10]. However, the continued evolution of SARS-CoV-2 has resulted in the emergence of multiple Omicron sub-lineages showing signs of convergent evolution by the acquisition of the same immune escape mutation in the RBD region of the Spike protein. Notably, all five recent convergent mutations are present in BQ. 1.1: R346T, K444T, L452R, N460K, or F486V [3]. Because of these newly acquired mutations, the benefits of bivalent compared to monovalent vaccines against this lineage remain to be established.

It is well accepted now that hybrid immunity leads to better immune responses and protection from severe outcomes than vaccination alone [11–17]. Because the original mRNA vaccines poorly prevent viral transmission, an important part of the vaccinated population have been recently infected by Omicron subvariants, leading to improved immune responses in these individuals compared to SARS-CoV-2 naïve individuals who have just been vaccinated.

In this study, we evaluated the capacity of plasma antibodies to recognize and neutralize the original D614G and the Omicron BQ.1.1 subvariant S four weeks (W4-Va3) and four months (M4-Va3) after the third dose and four weeks after the fourth dose (W4-Va4) of mRNA vaccines (Figure 1A). These participants mainly received as their first three doses of vaccine the Pfizer monovalent vaccine, and as the fourth dose either the Pfizer or Moderna monovalent or Pfizer (BA.4/5) or Moderna (BA.1) bivalent vaccines. We also measured the anti-nucleocapsid (N) level to determine if the donors had recent breakthrough infection (BTI), i.e., they have been infected between their third and fourth doses of vaccine by a Omicron sublineage. Basic demographic characteristics of the cohort are summarized in Table 1.

View this table:
Table 1. Characteristics of the SARS-CoV-2 vaccinated cohort
Figure 1.
Figure 1. Recognition and neutralization of the D614G and BQ.1.1 Spikes after the third and fourth doses of SARS-CoV-2 vaccine in individuals with or without a recent breakthrough infection.

(A) SARS-CoV-2 vaccine cohort design. The yellow box identifies the three timepoints under study shown in panels B, C, E and F and the red box the period presented in panels D and G. (B-D) 293T cells were transfected with the full-length D614G or BQ.1.1 S, stained with the CV3-25 mAb or with plasma from vaccinated individuals and analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 mAb binding. (E-G) Neutralization activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID50) values were determined using a normalized non-linear regression using GraphPad Prism software. Individuals vaccinated with Pfizer monovalent, Moderna monovalent, Pfizer bivalent (BA.4/5) or Moderna bivalent (BA.1) fourth dose are represented by orange, green, purple and blue points respectively. Limits of detection are plotted. Error bars indicate means ± SEM. (* P < 0.05; ** P < 0.01; **** P < 0.0001; ns, non-significant).

Materials and Methods

Ethics statement

The study was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. The protocol was approved by the Ethics Committee of CHUM (19.381, approved on February 28, 2022) and Héma-Québec (2022-016, approved on October 7, 2022).

Human subjects

The study was conducted in 63 individuals (25 males and 38 females; age range: 24-84 years). 20 of these individuals had recent breakthrough infection with an Omicron sublineage (9 males and 11 females; age range: 24-67 years), i.e. as determined by the increase in anti-N levels between W4-Va3 and M4-Va3 or between M4-Va3 and W4-Va4 using a recently described analytical approach [18] (Figure S1). For the other donors (16 males and 27 females; age range: 31-84 years), we did not observe a significant increase of the anti-N levels, although some of them have a history of infection. No other specific criteria such as number of patients (sample size), sex, clinical or demographic were used for inclusion.

Figure S1.
Figure S1. Anti-N level measured after the third and fourth doses of SARS-CoV-2 vaccine.

Anti-N level was measured in plasma from vaccinated donors by ELISA. Donors are considered to have a recent BTI when a significant increase of anti-N Abs level between W4-Va3 and M4-Va3 or between M4-Va3 and W4-Va4 is observed, according to a recently described analytical approach based on the ratio of anti-N absorbance. Individuals with no recent BTI and recent BTI are represented by gray and red dots respectively. (* P < 0.05; **** P < 0.0001; ns, non-significant).

Plasma samples and antibodies

Plasma samples were either recovered from whole blood or directly obtained from the PlasCov biobank [19], heat-inactivated for 1 hour at 56°C and stored at -80°C until use in subsequent experiments. Pre-pandemic plasma samples were used as negative controls in cytometry assays (data not shown). The conformationally independent S2-specific monoclonal antibody CV3-25 was used as a positive control and to normalize Spike expression in flow cytometry assays, as described [4,20–23]. Alexa Fluor-647-conjugated goat anti-human antibodies (Abs) able to detect all Ig isotypes (anti-human IgM+IgG+IgA; Jackson ImmunoResearch Laboratories, Cat # 109-605-064) were used as secondary Abs to detect plasma binding in flow cytometry experiments.

Plasmids

The plasmids encoding the SARS-CoV-2 D614G and BQ.1.1 Spike variants were previously described [4]. The pNL4.3 R-E-Luc plasmid was obtained from the NIH AIDS Reagent Program (Cat# 3418). The pIRES2-EGFP expressing plasmid was purchased from Clontech (Cat# 6029-1).

Cell lines

293T human embryonic kidney cells (obtained from ATCC, Cat# CRL-3216) were maintained at 37°C under 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (Wisent) containing 5% fetal bovine serum (FBS) (VWR) and 100 μg/ml of penicillin-streptomycin (Wisent). 293T-ACE2 cell line was previously reported [24].

Enzyme-linked immunosorbent assay (ELISA)

All samples were tested for anti-N total immunoglobulin levels using an in-house anti-N ELISA. The assay protocol is similar to the anti-SARS-CoV-2 RBD ELISA previously developed by our group [25], except that recombinant N (Centre National en Électrochimie et en Technologies Environnementales Inc., Shawinigan, Canada) was used (0.25 µg/ml) in lieu of the RBD antigen (2.5 µg/ml).

Cell surface staining and flow cytometry analysis

293T were transfected with full-length SARS-CoV-2 Spikes and a green fluorescent protein (GFP) expressor (pIRES2-eGFP) using the calcium-phosphate method. Two days post-transfection, Spike-expressing 293T cells were stained with the CV3-25 Ab (5 μg/mL) as control or plasma (1:250 dilution) for 45 min at 37°C. AlexaFluor-647-conjugated goat anti-human IgM+IgG+IgA (1/800 dilution) were used as secondary Abs. The percentage of Spike-expressing cells (GFP + cells) was determined by gating the living cell population based on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a LSRFortessa cytometer (BD Biosciences), and data analysis was performed using FlowJo v10.7.1 (Tree Star). The conformationally-independent anti-S2 antibody CV3-25, effective against all Spike variants, was used to normalize Spike expression, as reported [4,20,22,23]. The Median Fluorescence intensities (MFI) obtained with plasma were normalized to the MFI obtained with CV3-25 and presented as percentage of CV3-25 binding.

Virus neutralization assay

293T cells were transfected with the lentiviral vector pNL4.3 R-E− Luc and a plasmid encoding the D614G or the BQ.1.1 S glycoprotein at a ratio of 10:1 to produce SARS-CoV-2 pseudoviruses. Two days post-transfection, cell supernatants were harvested and stored at −80°C until use. For the neutralization assay, 293T-ACE2 target cells were seeded at a density of 1×104 cells/well in 96-well luminometer-compatible tissue culture plates (PerkinElmer) 24h before infection. Pseudoviral particles were incubated with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then added to the target cells followed by incubation for 48h at 37°C. Cells were lysed by the addition of 30 μL of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar luminometer (Berthold Technologies) was used to measure the luciferase activity of each well after the addition of 100 μL of luciferin buffer (15mM MgSO4, 15mM KH2PO4 [pH 7.8], 1mM ATP, and 1mM dithiothreitol) and 50 μL of 1mM d-luciferin potassium salt (Prolume). The neutralization half-maximal inhibitory dilution (ID50) represents the plasma dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

Statistical analysis

Symbols represent biologically independent samples from individuals. Statistics were analyzed using GraphPad Prism version 8.0.1 (GraphPad, San Diego, CA). Each dataset was tested for statistical normality and this information was used to apply the appropriate (parametric or nonparametric) statistical test. p values < 0.05 were considered significant; significance values are indicated as *P<0.05, **P<0.01, ***P<0.001, ***P<0.0001, ns, non-significant.

Results

We first monitored the capacity of plasma to recognize the D614G and BQ.1.1 Spikes after the third and fourth doses of mRNA vaccine by flow cytometry (Figure 1B-D). For the D614G S, no significant differences were observed four weeks and four months after the third dose of vaccine between individuals with or without recent BTI. In contrast, four weeks after the fourth dose of mRNA vaccine, individuals with recent BTI recognized better the D614G S than donors with no recent BTI regardless of the vaccine type received (Figure 1B). For the BQ.1.1 S, at the M4-Va3 timepoint donors with recent BTI better recognized the S than individuals with no recent infection, and this difference in recognition was more significant four weeks after the fourth dose (Figure 1C). The level of BQ.1.1 S recognition was significantly lower compared to D614G S in donors without recent BTI (Figure 1D), in agreement with recent reports [4,5]. In donors who had recently been infected, there was a significant but smaller difference in the level of recognition between the two Spikes compared to the other group.

We also measured the neutralizing activity of plasma against the D614G and BQ.1.1 S (Figure 1E-G). We observed pattern similar to that measured for Spike recognition. No significant differences were observed between the two groups at W4-Va3 and M4-Va3 timepoints (Figure 1E-F). In contrast, four weeks after the fourth dose, donors with recent BTI had a significantly higher level of neutralizing activity against D614G and BQ.1.1 S. All donors with recent BTI who received a fourth dose developed neutralizing antibodies against BQ.1.1 S, while some donors who just received four doses of vaccine were still not able to neutralize this Spike. As observed for S recognition (Figure 1D), BQ.1.1 Spike was significantly less neutralized than D614G S, even after four doses of mRNA vaccine (Figure 1G). However, the difference in neutralization between the two S was smaller in the group with recent BTI.

The Moderna BA.1 bivalent vaccine (blue points) tended to induce better recognition and neutralization than the other vaccine platforms including the Pfizer BA.4/5 bivalent vaccine with lesser decrease of recognition and neutralization of BQ.1.1 S (Figure 1B-G, Figure S2). These differences did not reach statistical significance; whether this is due to the relatively low number of samples tested remains to be determined.

Figure S2.
Figure S2. Recognition and neutralization of the D614G and BQ.1.1 Spikes after the fourth doses of SARS-CoV-2 vaccine in individuals with or without a recent breakthrough infection.

(A) 293T cells were transfected with the full-length D614G or BQ.1.1 S, stained with the CV3-25 mAb or with plasma from vaccinated individuals and analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 mAb binding. (B) Neutralization activity was measured by incubating pseudoviruses bearing SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID50) values were determined using a normalized non-linear regression using GraphPad Prism software. Individuals vaccinated with Pfizer monovalent, Moderna monovalent, Pfizer bivalent (BA.4/5) or Moderna bivalent (BA.1) fourth dose are represented by orange, green, purple and blue points respectively. Limits of detection are plotted. Error bars indicate means ± SEM.

Discussion

Since its emergence in late 2021, the Omicron variant continues to evolve into new subvariants that are increasingly resistant to monoclonal antibodies and vaccination [5,26–30]. To address vaccine resistance, bivalent mRNA vaccines, expressing both the original Spike and one of the parental lineages of Omicron (BA.1 or BA.4/5) Spike, have been developed and are now being administered in several jurisdictions worldwide. However, although the bivalent mRNA vaccine has been shown to increase the level of protection against BA.5 variant in mice [31], evidence of its superior effectiveness in the human population remains to be demonstrated, especially against sub-lineages with newly acquired immune escape mutations. Recent studies showed that both monovalent and bivalent vaccines induced low humoral responses against BQ.1.1, but recent breakthrough infection before vaccination strongly improved these responses [32]. The results presented herein support these observations.

As previously reported in numerous studies, including ours, hybrid immunity led to better humoral responses against the BQ.1.1 and other recent variants than just vaccination [4,5,32]. Also, we observed that after 4 doses of mRNA vaccine and no recent BTI, some donors did not have neutralizing activity against pseudoviral particles bearing the BQ.1.1 Spike. Whether these changes of recognition and neutralization translate into greater risk of severe disease is currently unknown. In contrast, BTI likely increased the breadth of neutralizing antibodies since all donors had detectable levels of neutralization against BQ.1.1.

These results indicate that further efforts have to be devoted to improve vaccines against new SARS-CoV-2 variants of concern. Whether immune responses comparable to those observed with breakthrough infections could be obtained with new vaccine formulations remains to be determined.

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Author Contributions

A.T., R.B. and A.F. conceived the study. A.T., M.B., H.M., J.P., G.G-L., R.B. and A.F. performed, analyzed, and interpreted the experiments. A.T. performed statistical analysis. H.M., G.G-L., M.C., and A.F. contributed unique reagents. L.G., P.A., C.M., C.T., D.E.K., Y.G. and V.M.-L. collected and provided clinical samples. R.B., G.D.S., and I.L. provided scientific input related to VOCs and vaccine efficacy. A.T. and A.F. wrote the manuscript with inputs from others. Every author has read, edited and approved the final manuscript.

Funding

This work was supported by le Ministère de l’Economie et de l’Innovation du Québec, Programme de soutien aux organismes de recherche et d’innovation to A.F. and by the Fondation du CHUM. This work was also supported by a CIHR foundation grant #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958, by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI) #41027 to A.F. The PlasCov biobank was supported by funding from the COVID-19 Immunity Task Force (CITF) which is supported by the Public Health Agency of Canada (PHAC). Work on variants presented was also supported by the Sentinelle COVID Quebec network led by the LSPQ in collaboration with Fonds de Recherche du Québec Santé (FRQS) to A.F. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235 950-232424. C.T. is the Pfizer/Université de Montréal Chair on HIV translational research. V.M.-L is supported by a FRQS Junior 2 salary award. A.T. was supported by MITACS Accélération postdoctoral fellowship. M.B. was the recipient of a CIHR master’s scholarship award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We declare no competing interests.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki in terms of informed consent and approval by an appropriate institutional board. The protocol was approved by the Ethics Committee of CHUM (19.381, approved on February 28, 2022) and Héma-Québec (2022-016, approved on October 7, 2022).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Further information, data reported in this paper, and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Andrés Finzi (andres.finzi{at}umontreal.ca) upon request.

Conflicts of Interest

The authors declare no conflict of interest.

Acknowledgments

The authors are grateful to the donors who participated in this study. The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical assistance.

References

  1. 1.↵
    Données sur les variants du SRAS-CoV-2 au Québec Available online: https://www.inspq.qc.ca/covid-19/donnees/variants (accessed on 6 December 2022).
  2. 2.↵
    CDC COVID Data Tracker Weekly Review Available online: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html (accessed on 6 December 2022).
  3. 3.↵
    Qu, P.; Evans, J.P.; Faraone, J.; Zheng, Y.-M.; Carlin, C.; Anghelina, M.; Stevens, P.; Fernandez, S.; Jones, D.; Lozanski, G.; et al. Enhanced Neutralization Resistance of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. Cell Host & Microbe 2022, doi:10.1016/j.chom.2022.11.012.
    OpenUrlCrossRef
  4. 4.↵
    Tauzin, A.; Nicolas, A.; Ding, S.; Benlarbi, M.; Medjahed, H.; Chatterjee, D.; Dionne, K.; Gong, S.Y.; Gendron-Lepage, G.; Bo, Y.; et al. SARS-CoV-2 Omicron Subvariants Spike Recognition and Neutralization Elicited after the Third Dose of MRNA Vaccine 2022, 2022.08.03.22278386.
  5. 5.↵
    Kurhade, C.; Zou, J.; Xia, H.; Liu, M.; Chang, H.C.; Ren, P.; Xie, X.; Shi, P.-Y. Low Neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by Parental MRNA Vaccine or a BA.5-Bivalent Booster. Nat Med 2022, 1–1, doi:10.1038/s41591-022-02162-x.
    OpenUrlCrossRef
  6. 6.↵
  7. 7.
    EMA First Adapted COVID-19 Booster Vaccines Recommended for Approval in the EU, https://Www.Ema.Europa.Eu/En/News/First-Adapted-Covid-19-Booster-Vaccines-Recommended-Approval-Eu Available online: https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu (accessed on 6 December 2022).
  8. 8.↵
  9. 9.↵
    Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine | Pfizer Available online: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-complete-submission-european-medicines (accessed on 6 December 2022).
  10. 10.↵
    Canada | SPIKEVAX™ Information Available online: https://www.modernacovid19global.com/ca/ (accessed on 6 December 2022).
  11. 11.↵
    Ntziora, F.; Kostaki, E.G.; Karapanou, A.; Mylona, M.; Tseti, I.; Sipsas, N.V.; Paraskevis, D.; Sfikakis, P.P. Protection of Vaccination versus Hybrid Immunity against Infection with COVID-19 Omicron Variants among Health-Care Workers. Vaccine 2022, 40, 7195–7200, doi:10.1016/j.vaccine.2022.09.042.
    OpenUrlCrossRef
  12. 12.
    Altarawneh, H.N.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Hasan, M.R.; Yassine, H.M.; Al-Khatib, H.A.; Smatti, M.K.; Coyle, P.; Al-Kanaani, Z.; et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022, 387, 21–34, doi:10.1056/NEJMoa2203965.
    OpenUrlCrossRef
  13. 13.
    Carazo, S.; Skowronski, D.M.; Brisson, M.; Barkati, S.; Sauvageau, C.; Brousseau, N.; Gilca, R.; Fafard, J.; Talbot, D.; Ouakki, M.; et al. Protection against Omicron (B.1.1.529) BA.2 Reinfection Conferred by Primary Omicron BA.1 or Pre-Omicron SARS-CoV-2 Infection among Health-Care Workers with and without MRNA Vaccination: A Test-Negative Case-Control Study. The Lancet Infectious Diseases 2022, 0, doi:10.1016/S1473-3099(22)00578-3.
    OpenUrlCrossRef
  14. 14.
    Tauzin, A.; Nayrac, M.; Benlarbi, M.; Gong, S.Y.; Gasser, R.; Beaudoin-Bussières, G.; Brassard, N.; Laumaea, A.; Vézina, D.; Prévost, J.; et al. A Single Dose of the SARS-CoV-2 Vaccine BNT162b2 Elicits Fc-Mediated Antibody Effector Functions and T Cell Responses. Cell Host & Microbe 2021, 0, doi:10.1016/j.chom.2021.06.001.
    OpenUrlCrossRefPubMed
  15. 15.
    Tauzin, A.; Gong, S.Y.; Beaudoin-Bussières, G.; Vézina, D.; Gasser, R.; Nault, L.; Marchitto, L.; Benlarbi, M.; Chatterjee, D.; Nayrac, M.; et al. Strong Humoral Immune Responses against SARS-CoV-2 Spike after BNT162b2 MRNA Vaccination with a 16-Week Interval between Doses. Cell Host & Microbe 2022, 30, 97-109.e5, doi:10.1016/j.chom.2021.12.004.
    OpenUrlCrossRefPubMed
  16. 16.
    Stamatatos, L.; Czartoski, J.; Wan, Y.-H.; Homad, L.J.; Rubin, V.; Glantz, H.; Neradilek, M.; Seydoux, E.; Jennewein, M.F.; MacCamy, A.J.; et al. MRNA Vaccination Boosts Cross-Variant Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. Science 2021, eabg9175, doi:10.1126/science.abg9175.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Tauzin, A.; Gong, S.Y.; Chatterjee, D.; Ding, S.; Painter, M.M.; Goel, R.R.; Beaudoin-Bussières, G.; Marchitto, L.; Boutin, M.; Laumaea, A.; et al. A Boost with SARS-CoV-2 BNT162b2 MRNA Vaccine Elicits Strong Humoral Responses Independently of the Interval between the First Two Doses. Cell Reports 2022, 41, doi:10.1016/j.celrep.2022.111554.
    OpenUrlCrossRef
  18. 18.↵
    Bazin, R.; Rochette, S.; Perreault, J.; Fournier, M.-J.; Grégoire, Y.; Boivin, A.; Lewin, A.; Germain, M.; Renaud, C. Development and Use of a Method Based on the Anti-N Reactivity of Longitudinal Samples to Better Estimate SARS-CoV-2 Seroprevalence in a Vaccinated Population 2022, 2022.08.15.22278798.
  19. 19.↵
    Germain, M.; Lewin, A.; Bazin, R.; Dieudé, M.; Perreault, J.; Boivin, A.; Grégoire, Y.; Renaud, C. Cohort Profile: A Québec-Based Plasma Donor Biobank to Study COVID-19 Immunity (PlasCoV) 2022, 2022.11.09.22282156.
  20. 20.↵
    Prévost, J.; Richard, J.; Gasser, R.; Ding, S.; Fage, C.; Anand, S.P.; Adam, D.; Vergara, N.G.; Tauzin, A.; Benlarbi, M.; et al. Impact of Temperature on the Affinity of SARS-CoV-2 Spike Glycoprotein for Host ACE2. J Biol Chem 2021, 101151, doi:10.1016/j.jbc.2021.101151.
    OpenUrlCrossRef
  21. 21.
    Jennewein, M.F.; MacCamy, A.J.; Akins, N.R.; Feng, J.; Homad, L.J.; Hurlburt, N.K.; Seydoux, E.; Wan, Y.-H.; Stuart, A.B.; Edara, V.V.; et al. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. Cell Rep 2021, 36, 109353, doi:10.1016/j.celrep.2021.109353.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Gong, S.Y.; Chatterjee, D.; Richard, J.; Prévost, J.; Tauzin, A.; Gasser, R.; Bo, Y.; Vézina, D.; Goyette, G.; Gendron-Lepage, G.; et al. Contribution of Single Mutations to Selected SARS-CoV-2 Emerging Variants Spike Antigenicity. Virology 2021, 563, 134–145, doi:10.1016/j.virol.2021.09.001.
    OpenUrlCrossRef
  23. 23.↵
    Chatterjee, D.; Tauzin, A.; Marchitto, L.; Gong, S.Y.; Boutin, M.; Bourassa, C.; Beaudoin-Bussières, G.; Bo, Y.; Ding, S.; Laumaea, A.; et al. SARS-CoV-2 Omicron Spike Recognition by Plasma from Individuals Receiving BNT162b2 MRNA Vaccination with a 16-Week Interval between Doses. Cell Rep 2022, 110429, doi:10.1016/j.celrep.2022.110429.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Prévost, J.; Gasser, R.; Beaudoin-Bussières, G.; Richard, J.; Duerr, R.; Laumaea, A.; Anand, S.P.; Goyette, G.; Benlarbi, M.; Ding, S.; et al. Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Rep Med 2020, 1, 100126, doi:10.1016/j.xcrm.2020.100126.
    OpenUrlCrossRef
  25. 25.↵
    Perreault, J.; Tremblay, T.; Fournier, M.-J.; Drouin, M.; Beaudoin-Bussières, G.; Prévost, J.; Lewin, A.; Bégin, P.; Finzi, A.; Bazin, R. Waning of SARS-CoV-2 RBD Antibodies in Longitudinal Convalescent Plasma Samples within 4 Months after Symptom Onset. Blood 2020, 136, 2588–2591, doi:10.1182/blood.2020008367.
    OpenUrlCrossRef
  26. 26.↵
    Qu, P.; Faraone, J.; Evans, J.P.; Zou, X.; Zheng, Y.-M.; Carlin, C.; Bednash, J.S.; Lozanski, G.; Mallampalli, R.K.; Saif, L.J.; et al. Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. New England Journal of Medicine 2022, 386, 2526–2528, doi:10.1056/NEJMc2206725.
    OpenUrlCrossRefPubMed
  27. 27.
    Tuekprakhon, A.; Nutalai, R.; Dijokaite-Guraliuc, A.; Zhou, D.; Ginn, H.M.; Selvaraj, M.; Liu, C.; Mentzer, A.J.; Supasa, P.; Duyvesteyn, H.M.E.; et al. Antibody Escape of SARS-CoV-2 Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum. Cell 2022, 185, 2422-2433.e13, doi:10.1016/j.cell.2022.06.005.
    OpenUrlCrossRefPubMed
  28. 28.
    Wang, Q.; Guo, Y.; Iketani, S.; Nair, M.S.; Li, Z.; Mohri, H.; Wang, M.; Yu, J.; Bowen, A.D.; Chang, J.Y.; et al. Antibody Evasion by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, & BA.5. Nature 2022, 1–3, doi:10.1038/s41586-022-05053-w.
    OpenUrlCrossRef
  29. 29.
    Sheward, D.J.; Kim, C.; Fischbach, J.; Sato, K.; Muschiol, S.; Ehling, R.A.; Björkström, N.K.; Hedestam, G.B.K.; Reddy, S.T.; Albert, J.; et al. Omicron Sublineage BA.2.75.2 Exhibits Extensive Escape from Neutralising Antibodies. The Lancet Infectious Diseases 2022, 0, doi:10.1016/S1473-3099(22)00663-6.
    OpenUrlCrossRef
  30. 30.↵
    Arora, P.; Kempf, A.; Nehlmeier, I.; Schulz, S.R.; Jäck, H.-M.; Pöhlmann, S.; Hoffmann, M. Omicron Sublineage BQ.1.1 Resistance to Monoclonal Antibodies. The Lancet Infectious Diseases 2022, 0, doi:10.1016/S1473-3099(22)00733-2.
    OpenUrlCrossRef
  31. 31.↵
    Scheaffer, S.M.; Lee, D.; Whitener, B.; Ying, B.; Wu, K.; Liang, C.-Y.; Jani, H.; Martin, P.; Amato, N.J.; Avena, L.E.; et al. Bivalent SARS-CoV-2 MRNA Vaccines Increase Breadth of Neutralization and Protect against the BA.5 Omicron Variant in Mice. Nat Med 2022, 1–11, doi:10.1038/s41591-022-02092-8.
    OpenUrlCrossRef
  32. 32.↵
    Hoffmann, M.; Behrens, G.M.N.; Arora, P.; Kempf, A.; Nehlmeier, I.; Cossmann, A.; Manthey, L.; Dopfer-Jablonka, A.; Pöhlmann, S. Effect of Hybrid Immunity and Bivalent Booster Vaccination on Omicron Sublineage Neutralisation. The Lancet Infectious Diseases 2022, 0, doi:10.1016/S1473-3099(22)00792-7.
    OpenUrlCrossRef
Back to top
Posted December 20, 2022.
Download PDF
Data/Code
Email
Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-CoV-2 mRNA vaccination
Alexandra Tauzin, Mehdi Benlarbi, Halima Medjahed, Yves Grégoire, Josée Perreault, Gabrielle Gendron-Lepage, Laurie Gokool, Chantal Morisseau, Pascale Arlotto, Cécile Tremblay, Daniel E. Kaufmann, Valérie-Martel-Laferrière, Inès Levade, Marceline Côté, Gaston de Serres, Renée Bazin, Andrés Finzi
medRxiv 2022.12.20.22283723; doi: https://doi.org/10.1101/2022.12.20.22283723
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area